Quant MF's Bold 2026 Call: Pharma is 'No-Brainer', Warns on Hype Stocks!

Quant MF CIO Flags Pharma as Top 2026 Pick, Warns Against Hype

Sandeep Tandon, Founder and Chief Investment Officer of Quant Mutual Fund, has issued a stark warning to investors heading into 2026. He urges a departure from the hype and inflated narratives that dominated 2025, advocating for a disciplined, data-driven investment strategy centered on valuation comfort, liquidity, and downside protection. Tandon highlighted the market's susceptibility to extreme greed in the past year, drawing even seasoned professionals into frothy stocks despite red flags like promoter and private equity exits.

Caution on Mid and Small Caps

While many portfolios felt the sting of mid- and small-cap underperformance in 2025, Tandon does not foresee a broad-based recovery. Instead, he anticipates a selective rebound, benefiting only those stocks trading at reasonable valuations, especially those that are under-owned and reside in neglected market segments. Stocks that were excessively hyped and priced for perfection, he cautioned, are likely to face further declines, suggesting the pain for these expensive names has only just begun.

Macro Outlook Brighter for 2026

Comparing the outlook for early 2026 with the previous year, Tandon perceives a materially stronger macro environment in India. He points to signs of a bottoming process, exhaustion in foreign institutional selling, and government initiatives aimed at boosting consumption. This suggests 2026 could be a year of recovery and stabilization after the peaking phase observed in 2025.

Sector Opportunities and Risks

Stocks closely tied to the real economy are expected to perform better in 2026. Tandon sees potential in NBFCs, banks, and large infrastructure companies, many of which have undergone significant corrections or consolidations, improving their risk-reward profiles. Conversely, he remains highly critical of expensive new-age IPOs, predicting continued supply overhang from private equity exits and inevitable capitulation for many. He noted that Indian tech stocks, unlike their global peers, became excessively expensive due to a limited set of opportunities attracting extraordinary capital.

Pharma: The 'No-Brainer' Bet

Among all sectors, pharmaceuticals stand out as Tandon's highest conviction call for 2026 and beyond. He described the Indian pharma sector as a "decadal opportunity," citing its global dominance in generics, a robust US FDA-approved manufacturing base, and expansion into complex areas like Contract Development and Manufacturing Organization (CDMO), biologics, and novel therapies. Tandon unequivocally stated that pharma is a "no-brainer" investment, offering protected downside and significant upside potential, further supported by potential currency tailwinds from a weaker dollar.

Financials and Other Sectors

Within the financial services space, Tandon continues to favor NBFCs, believing they still have growth potential. He also highlighted insurance companies, particularly life insurers, as being in "neglected zones" and attractive for investment. Quant Mutual Fund has recently increased its exposure to insurance stocks as sector headwinds ease. While structurally positive on defence stocks due to geopolitical factors, Tandon cautioned that current valuations already price in substantial future growth, recommending a buy-on-dips approach. For metals, he remains constructive but cautious due to global uncertainties, preferring tactical exposure over large allocations.

Portfolio Construction

Quant Mutual Fund is not adopting a cash-heavy strategy but maintains a cautious stance. The fund is building exposure in traditional companies, liquid, beaten-down stocks, and businesses in the "hated or ignored" category. The investment priority for 2026 is clearly defined as Liquidity, Safety, and then Returns.

Impact

This outlook from a prominent fund manager like Sandeep Tandon can significantly influence investor sentiment and capital allocation within the Indian stock market. His specific calls on pharmaceuticals, NBFCs, and insurance, alongside his warnings on hyped stocks and new-age IPOs, could steer investment flows. The emphasis on valuation and risk management suggests a potential shift towards more fundamental-driven investing, away from speculative rallies. The predicted improvement in the macro environment could also boost overall market confidence. Impact Rating: 8/10

Difficult Terms Explained

Hype-driven rallies: Stock price increases fueled by excessive excitement and speculation rather than solid financial performance or fundamentals.
Valuation comfort: Investing in assets whose current market price is considered reasonable or undervalued relative to their intrinsic worth or future earning potential.
Liquidity: The ease with which an asset can be bought or sold in the market without significantly affecting its price.
Downside protection: Investment strategies or assets designed to limit potential losses.
Promoter selling: When the founders or original owners of a company sell their shares.
Private equity exits: When private equity firms sell their stake in a company, often to realize profits.
Frothy stocks: Stocks whose prices have risen excessively and are considered overvalued, carrying a high risk of a sharp decline.
Cycle peaks: The highest point in a market or economic cycle, after which a downturn is expected.
Mid and small caps: Refers to companies with medium and small market capitalization, respectively, which are often more volatile than large-cap companies.
Under-owned: Securities that a relatively small number of investors hold, suggesting potential for increased demand if they gain favor.
Neglected zones: Market segments or stocks that have been overlooked by most investors.
Priced for perfection: When a stock's valuation assumes an ideal scenario of continuous growth and success, leaving little room for error.
Macro environment: The overall state of the economy, including factors like inflation, interest rates, economic growth, and government policy.
Bottoming process: A period where an asset's price decline slows, stabilizes, and begins to show signs of potential recovery.
Foreign institutional selling: When foreign investors sell their holdings in a country's stock market.
New-age IPOs: Initial Public Offerings (IPOs) from relatively new companies, often in the technology or digital sector.
Capitulation: A phase in a declining market where investors sell their holdings in large numbers out of fear, marking a potential market bottom.
Supply overhang: A situation where there is a large amount of a security available for sale, potentially suppressing its price.
Global peers: Companies operating in the same industry or sector but based in different countries.
Cash positions: The amount of cash held by an investment fund or company.
Beaten-down stocks: Stocks whose prices have fallen significantly, often due to negative sentiment or temporary issues.
Hated or ignored zone: Market segments or stocks that are unpopular or overlooked by investors.
Buy-on-dips: An investment strategy of purchasing an asset when its price temporarily falls.
Geopolitics: The influence of political factors on international relations and global events.
Tactical exposure: Short-term investment allocation adjusted based on market conditions or specific opportunities.
Generics: Off-patent drugs that are equivalent to branded drugs in dosage, safety, strength, and route of administration.
CDMO (Contract Development and Manufacturing Organization): A company that provides drug development and manufacturing services to other pharmaceutical companies on a contract basis.
Biologics: Therapeutic products derived from living organisms or their components.
Decadal opportunity: An investment prospect expected to yield significant returns over a ten-year period.
Alpha generation: Achieving investment returns that exceed a benchmark index or market average.
Currency tailwinds: Favorable movements in exchange rates that benefit a company or country's exports or investments.
NBFCs (Non-Banking Financial Companies): Financial institutions that provide banking-like services but do not hold a full banking license.
Life insurance: Insurance providing a payout upon the death of the insured person.